ClinicalTrials.gg
Status unknownNCT05492981EVAUpdated Aug 9, 2022

Does an Educational Video for Aneuploidy Screening Improve Informed Choice Among Pregnant Women?

An interventional study of Enhanced (intervention) education in Aneuploidy, Down Syndrome and Pregnancy Early, sponsored by National University Hospital, Singapore. Status unknown at 1 site in Singapore. Open to female participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Screening

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2021, registered Jul 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
Female
01

Study summary

Informed decision-making regarding aneuploidy screening has been reported to be low. Poor knowledge and the lack of deliberation have been cited as reasons for uninformed choices, highlighting the need for adequate pre-test counselling. We conducted a study to assess if an educational video improves informed choice in a clinical setting where both the combined first trimester screen and non-invasive prenatal screening are offered routinely to pregnant women.

Read the detailed description

Women attending the antenatal clinic with a viable singleton pregnancy below 14 weeks were randomized to receive routine counselling by their obstetrician or the intervention, where they watched a 16-minute educational video on aneuploidy screening before their consult. The primary outcome, rate of informed choice, was assessed using an adapted multidimensional measure of informed choice (MMIC) questionnaire, where informed choice was defined as good knowledge and value-consistent behaviour. Secondary outcomes included informed choice with deliberation, decisional conflict and anxiety.

02

Conditions studied

  • Aneuploidy
  • Down Syndrome
  • Pregnancy Early

Keywords

  • prenatal
  • Screening
  • informed choice
  • randomized controlled trial
03

In context

Aneuploidy

73 studies on the registry are indexed under Aneuploidy; 10 are open to participants now.

This study's enrollment of 286 is above the median of 200 across 34 interventional studies indexed under Aneuploidy.

Browse Aneuploidy studies →

Lead sponsor

National University Hospital, Singapore is the lead sponsor of 454 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 21 years or older
  • English speaking
  • had a viable singleton pregnancy below 14 weeks gestation

Exclusion criteria

Exclusion Criteria:

  • women who had any prior discussion with a clinician regarding aneuploidy screening for their current pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Intervention

    The intervention was a 16-minute educational video created by the study investigators which provided information about Down syndrome, diagnostic tests and screening tests. The screening tests covered in the video included the triple test, the combined first trimester screen and non-invasive prenatal screening. Information about how and when each of the tests were performed, their detection rates and possible results and their interpretations were covered in the video. The video was viewed by several healthcare providers and experts in the field of prenatal screening before the commencement of this study to ensure that the content was appropriate and adequate. The intervention was viewed by subjects on a portable tablet in a quiet room in the antenatal clinic. Subjects were then invited to ask their doctor any questions that they may have had about the video during the clinic consult which followed.

    Behavioral: Enhanced (intervention) education

  • No intervention
    Control

    Women in the control group were counselled by the referring doctor regarding the aneuploidy screening options of FTS or NIPS, and provided information about the procedures involved for each test, their detection rates, cost, and possible results of testing. The use of a written information leaflet was available to doctors as an adjunct to providing this information.

Interventions

  • BehavioralEnhanced (intervention) education

    See arm description

06

What researchers measure

Primary outcomes

  1. Informed choice

    Outcome will be measured using the modified multidimensional measure of informed choice (MMIC).

    Time frame: Day 0

Secondary outcomes

  1. Deliberation

    Outcome will be measured using 6 questions to measure deliberation on a five-point Likert scale

    Time frame: Day 0

  2. Knowledge

    Outcome will be measured using a 19-item validated true/false knowledge questionnaire.

    Time frame: Day 0

  3. Value-consistent behaviour

    Attitudes towards testing options were assessed using a validated questionnaire and deemed to be value consistent if a participants had a positive attitude towards the test option that they chose, or a negative attitude towards all test options and chose not to test.

    Time frame: Day 0

  4. anxiety

    Anxiety was assessed using the Spielberger State trait anxiety inventory (STAI-6) short form which consisted of 6 items

    Time frame: Day 0

  5. Decisional Conflict

    Decisional conflict was measured using a validated Decisional Conflict Scale (DCS)

    Time frame: Day 0

07

Study locations

1 site
  • National University Hospital
    Singapore, 119074, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2022, 7 months.

Of 19 interventional studies with no phase under Aneuploidy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2022
First posted
Aug 9, 2022
StartActual
Jul 5, 2021
Primary completionActual
Feb 24, 2022
CompletionEst.
Jul 30, 2022
Last update
Aug 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05492981
Responsible party
Sponsor
First posted
Aug 9, 2022
Start date
Jul 5, 2021
Primary completion
Feb 24, 2022
Completion
Jul 30, 2022 (estimated)
Last update
Aug 9, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion